Implandata Ophthalmic Products received CE mark approval for its next-generation EYEMATE-IO 1.1 implantable micro-sensor, which will be launched in April. The EYEMATE-IO enables eye surgeons to place the permanent implantable eye pressure sensor in conjunction with cataract surgery through significantly smaller incisions. The micro-sensor performs continual monitoring of eye pressure in glaucoma patients, providing critical information for guided glaucoma therapy.
“Implanting the next-generation intraocular micro-sensor is almost a minor intervention in the hands of an experienced surgeon and can be performed during cataract surgery without any major hassle and without increasing the likelihood of complications,” Prof. med. Burkhard Dick, Director of the University Eye Clinic of Knappschaftskrankenhaus Bochum and current President of the German Society for Cataract & Refractive Surgeons, said in a company news release. “From the surgeon’s point of view, this further miniaturization is a major breakthrough and has the potential to render the sensor a valuable and reliable tool for monitoring IOP. Given the relatively high proportion of cataract patients who also suffer from glaucoma, we can expect to implant ever larger numbers of these microsensors in the foreseeable future.”
Volker Dockhorn, CEO of Medicel AG, Altenrhein/Switzerland, which is manufacturing the customized ACCUJECT EM-IO 1.1 delivery system for Implandata, said, “We are delighted to be working with Implandata on this exciting product. The injection of the implantable microsensor EYEMATE-IO 1.1 is one of these exciting challenges that we are happy to face when it comes to injecting new innovative implants into the eye. With the ACCUJECT injector platform specially adapted to the EYEMATE-IO 1.1 sensor, the surgeon can now reduce the required incision size down to less than 3.2 mm.”
“In contrast to the sporadic readings obtained in standard clinical practice, the EYEMATE system provides actionable IOP measurements throughout the 24 hours period and outside the ophthalmologist’s office, enhancing treatment options and contributing to less progressing vision loss in glaucoma patients,” Implandata’s CEO Max Ostermeier said in the news release. “As the EYEMATE system provides direct feedback to the patient in a home setting – information previously unavailable to the patient – therapy compliance will be improved, as already observed in earlier studies.”
Implandata is currently preparing for an initial market launch of its products at EYEMATE clinical ‘Centers of Excellence’ in Germany and Switzerland in 2019, followed by further internationalization in 2020 and the subsequent years.